



*"People
helping people
help
themselves"*

Mitchell E. Daniels, Jr., Governor
State of Indiana

Indiana Family and Social Services Administration

402 W. WASHINGTON STREET, P.O. BOX 7083
INDIANAPOLIS, IN 46207-7083

Anne W. Murphy, Secretary

MEETING AGENDA AND PUBLIC NOTIFICATION

Therapeutics Committee

February 5, 2010

9:00 A.M.

Conference Center Room "C"

Indiana State Government Center South

1. Call to Order-Chair
2. Opening Comments-OMPP
3. Approval of Memoranda, Meetings of November 6, 2009
4. Election of Officers, CY 2010
5. Preferred Drug List: Therapeutic Class Re-Review

+ Respiratory

- i. Beta Agonists
- ii. Leukotriene Inhibitors
- iii. Non-sedating Antihistamines
- iv. Nasal Preparations
- v. Oral Inhaled Corticosteroids
- vi. Beta Adrenergic and Corticosteroid Combinations
- vii. Agents to Treat COPD
- viii. Synagis
- ix. Xolair

+ Antiinfectives



- i. Antiherpetic Agents
 - ii. Antiviral (influenza) Agents
 - iii. First- and Third-Generation Cephalosporins
 - iv. Fluoroquinolones
 - v. Hepatitis C Agents
 - vi. Macrolides
 - vii. Ketolides
 - viii. Ophthalmic Antibiotics
 - ix. Otic Antibiotics
 - x. Systemic Antifungals
 - xi. Topical Antifungals
 - xii. Topical Antivirals
 - xiii. Vaginal Antimicrobials
- + Cardiovascular
- i. ACE Inhibitors
 - ii. ACE Inhibitors in combination with CCBs
 - iii. ACE Inhibitors in combination with Diuretics
 - iv. ARBs
 - v. ARBs in combination with CCBs
 - vi. ARBs in combination with CCBs and Diuretics
 - vii. ARBs in combination with Diuretics
 - viii. Alpha-Beta Blockers
 - ix. Beta Blockers
 - x. Beta Blockers in combination with Diuretics
 - xi. Calcium Channel Blockers
 - xii. HMG CoA and Calcium Channel Blocker Combination
 - xiii. Direct Renin Inhibitor
 - xiv. Direct Renin Inhibitor and ARB Combination
 - xv. Direct Renin Inhibitor and Diuretic Combination
 - xvi. Selective Aldosterone Receptor Antagonist (Inspra)
- + Lipotropics

- i. Bile Acid Sequestrants
- ii. Fibric Acid Derivatives
- iii. HMG CoA Reductase Inhibitors
- iv. Other Lipotropics

+ Triptans

+ Electrolyte Depleters

+ MS Agents

+ Effient–DUR Board Request for Re-review, SmartPA rule to be presented

+ Topical Antiparasitics–DUR Board Request for Re-evaluation of quantity limit

6. Proposed New Therapeutic Classes for May 2010 Review

- i. Anti-Ulcer Preparations (Carafate and Cytotec)
- ii. Ear Preparations (Aero Otic HC, Vosol, and Vosol HC)
- iii. Eye Anti-inflammatory Agents (Xibrom, Voltaren, Ocufer, Nevanac, and Acular)
- iv. Nsaid and Prostaglandin Combination (Arthrotec)
- v. Ophthalmic Anti-inflammatory Immodulator-Type (Restasis)

7. Update Regarding Specialty Pharmaceutical PDL

8. Presentation of Effient SmartPA Rule

9. Public Comment

10. Other Business

11. Adjourn